HU 003

Drug Profile

HU 003

Alternative Names: HU003

Latest Information Update: 17 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Huons
  • Class Anti-inflammatories; Antibacterials; Antiseptics; Herbal medicines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sepsis

Most Recent Events

  • 17 Dec 2015 No development reported - Phase-I for Sepsis in South Korea (unspecified route)
  • 31 Dec 2013 Huons has a patent that protects a method to prepare a purified extract of Lonicera japonica and its use in the treatment of Sepsis, in South Korea (Huons website, December 2015)
  • 31 Dec 2013 Phase-I clinical trials in Sepsis in South Korea (unspecified route) (Huons pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top